128 related articles for article (PubMed ID: 25178697)
1. Dose-independent confusion induced by voriconazole in a patient with Asian ancestry after allogeneic hematopoietic stem cell transplant.
Hui J
J Oncol Pharm Pract; 2016 Feb; 22(1):175-8. PubMed ID: 25178697
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of CYP2C19 Genotype-Guided Voriconazole Prophylaxis After Allogeneic Hematopoietic Cell Transplant.
Patel JN; Hamadeh IS; Robinson M; Shahid Z; Symanowski J; Steuerwald N; Hamilton A; Reese ES; Plesca DC; Arnall J; Taylor M; Trivedi J; Grunwald MR; Gerber J; Ghosh N; Avalos B; Copelan E
Clin Pharmacol Ther; 2020 Mar; 107(3):571-579. PubMed ID: 31549386
[TBL] [Abstract][Full Text] [Related]
3. Genotype-Directed Dosing Leads to Optimized Voriconazole Levels in Pediatric Patients Receiving Hematopoietic Stem Cell Transplantation.
Teusink A; Vinks A; Zhang K; Davies S; Fukuda T; Lane A; Nortman S; Kissell D; Dell S; Filipovich A; Mehta P
Biol Blood Marrow Transplant; 2016 Mar; 22(3):482-6. PubMed ID: 26616742
[TBL] [Abstract][Full Text] [Related]
4. Reasons for voriconazole prophylaxis discontinuation in allogeneic hematopoietic cell transplant recipients: A real-life paradigm.
Chan SY; Hughes RM; Woo K; Perales MA; Neofytos D; Papanicolaou G
Med Mycol; 2020 Nov; 58(8):1029-1036. PubMed ID: 32171012
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and safety of 14 days intravenous voriconazole in allogeneic haematopoietic stem cell transplant recipients.
Brüggemann RJ; Blijlevens NM; Burger DM; Franke B; Troke PF; Donnelly JP
J Antimicrob Chemother; 2010 Jan; 65(1):107-13. PubMed ID: 19933691
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetics may influence the impact of inflammation on voriconazole trough concentrations.
Gautier-Veyret E; Bailly S; Fonrose X; Tonini J; Chevalier S; Thiebaut-Bertrand A; Stanke-Labesque F
Pharmacogenomics; 2017 Aug; 18(12):1119-1123. PubMed ID: 28745547
[TBL] [Abstract][Full Text] [Related]
7. Voriconazole Dosing in Children Younger Than 3 Years Undergoing Cancer Chemotherapy or Hematopoietic Stem Cell Transplantation.
Yan SQ; Seyboth B; Kobos R; Eaton A; Seo SK; Cohen N
J Pediatric Infect Dis Soc; 2018 May; 7(2):169-171. PubMed ID: 28407118
[TBL] [Abstract][Full Text] [Related]
8. Effect of Therapeutic Drug Monitoring and Cytochrome P450 2C19 Genotyping on Clinical Outcomes of Voriconazole: A Systematic Review.
Lee J; Ng P; Hamandi B; Husain S; Lefebvre MJ; Battistella M
Ann Pharmacother; 2021 Apr; 55(4):509-529. PubMed ID: 32772568
[TBL] [Abstract][Full Text] [Related]
9. Influencing risk factors of voriconazole-induced liver injury in Uygur pediatric patients undergoing allogeneic hematopoietic stem cell transplantation.
Zhao T; Zhang HL; Shen H; Feng J; Wang TT; Li HJ; Yu LH
BMC Pediatr; 2024 May; 24(1):299. PubMed ID: 38702595
[TBL] [Abstract][Full Text] [Related]
10. An open-label trial of the prophylactic administration of voriconazole in patients who undergo allogeneic hematopoietic stem cell transplantation: study protocol.
Kunitomi A; Hasegawa Y; Hashimoto H; Saito AM; Iida H
Nagoya J Med Sci; 2018 Nov; 80(4):591-595. PubMed ID: 30587873
[TBL] [Abstract][Full Text] [Related]
11. Correlation of Pain and Fluoride Concentration in Allogeneic Hematopoietic Stem Cell Transplant Recipients on Voriconazole.
Barajas MR; McCullough KB; Merten JA; Dierkhising RA; Bartoo GT; Hashmi SK; Hogan WJ; Litzow MR; Patnaik MM; Wilson JW; Wolf RC; Wermers RA
Biol Blood Marrow Transplant; 2016 Mar; 22(3):579-83. PubMed ID: 26524731
[TBL] [Abstract][Full Text] [Related]
12. Safety of voriconazole and sirolimus coadministration after allogeneic hematopoietic SCT.
Ceberio I; Dai K; Devlin SM; Barker JN; Castro-Malaspina H; Goldberg JD; Giralt S; Adel NG; Perales MA
Bone Marrow Transplant; 2015 Mar; 50(3):438-43. PubMed ID: 25599164
[TBL] [Abstract][Full Text] [Related]
13. High-risk cutaneous squamous cell carcinoma in a Japanese allogeneic bone marrow transplant recipient on long-term voriconazole.
Ng W; Takahashi A; Muto Y; Yamazaki N
J Dermatol; 2017 Oct; 44(10):1152-1155. PubMed ID: 28470790
[TBL] [Abstract][Full Text] [Related]
14. Impact of
Suetsugu K; Mori Y; Yamamoto N; Shigematsu T; Miyamoto T; Egashira N; Akashi K; Masuda S
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31096684
[TBL] [Abstract][Full Text] [Related]
15. Lung transplant recipients receiving voriconazole and skin squamous cell carcinoma risk in Australia.
Neoh CF; Snell GI; Levvey B; Kotsimbos T; Morrissey O; Slavin MA; Stewart K; Kong DC
Med J Aust; 2014 Nov; 201(9):543-4. PubMed ID: 25358582
[No Abstract] [Full Text] [Related]
16. Rifampin-sirolimus-voriconazole interaction in a hematopoietic cell transplant recipient.
Wasko JA; Westholder JS; Jacobson PA
J Oncol Pharm Pract; 2017 Jan; 23(1):75-79. PubMed ID: 26763003
[TBL] [Abstract][Full Text] [Related]
17. Serum C-reactive protein levels affect the plasma voriconazole trough levels in allogeneic hematopoietic cell transplant recipients.
Yasu T; Konuma T; Kato S; Kurokawa Y; Takahashi S; Tojo A
Leuk Lymphoma; 2017 Nov; 58(11):2731-2733. PubMed ID: 28306482
[No Abstract] [Full Text] [Related]
18. Population Pharmacokinetics of Voriconazole in Chinese Patients with Hematopoietic Stem Cell Transplantation.
Chen C; Yang T; Li X; Ma L; Liu Y; Zhou Y; Ren H; Cui Y
Eur J Drug Metab Pharmacokinet; 2019 Oct; 44(5):659-668. PubMed ID: 31041728
[TBL] [Abstract][Full Text] [Related]
19. Worsening pneumonitis due to a pharmacokinetic drug-drug interaction between everolimus and voriconazole in a renal transplant patient.
Lecefel C; Eloy P; Chauvin B; Wyplosz B; Amilien V; Massias L; Taburet AM; Francois H; Furlan V
J Clin Pharm Ther; 2015 Feb; 40(1):119-20. PubMed ID: 25417855
[TBL] [Abstract][Full Text] [Related]
20. Impact of CYP2C19 Genotype and Drug Interactions on Voriconazole Plasma Concentrations: A Spain Pharmacogenetic-Pharmacokinetic Prospective Multicenter Study.
Blanco-Dorado S; Maroñas O; Latorre-Pellicer A; Rodríguez Jato MT; López-Vizcaíno A; Gómez Márquez A; Bardán García B; Belles Medall D; Barbeito Castiñeiras G; Pérez Del Molino Bernal ML; Campos-Toimil M; Otero Espinar F; Blanco Hortas A; Durán Piñeiro G; Zarra Ferro I; Carracedo Á; Lamas MJ; Fernández-Ferreiro A
Pharmacotherapy; 2020 Jan; 40(1):17-25. PubMed ID: 31782536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
